A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

PHASE1CompletedINTERVENTIONAL

Enrollment

256

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

Filgrastim Hospira

5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.

BIOLOGICAL

US-Approved Neupogen

5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.

Trial Locations (3)

Seaview Jacksonville LLC, Jacksonville

SeaView Research, Inc., Miami

SeaView Research, Inc., Coral Gables